Barclays’s Travere Therapeutics TVTX Stock Holding History

Barclays’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30,000	Closed	-$444K	–	5737
2025 Q2	$444K	Buy	+30,000	New	+$497K	﹤0.01%	3823
2024 Q1	–	Sell	-109,400	Closed	-$984K	–	5371
2023 Q4	$984K	Buy	+109,400	New	+$797K	﹤0.01%	3444
2019 Q3	–	Sell	-100,000	Closed	-$2.01M	–	7134
2019 Q2	$2.01M	Buy	+100,000	New	+$1.97M	﹤0.01%	2907
2017 Q4	–	Sell	-144,200	Closed	-$3.59M	–	7120
2017 Q3	$3.59M	Buy	+144,200	New	+$3.18M	﹤0.01%	1797
2017 Q2	–	Sell	-100	Closed	-$2K	–	6937
2017 Q1	$2K	Sell	100 -500	-83%	-$9.78K	﹤0.01%	6498
2016 Q4	$11K	Buy	+600	New	+$12.3K	﹤0.01%	5872
2016 Q1	–	Sell	-155,800	Closed	-$2.96M	–	6439
2015 Q4	$2.96M	Buy	155,800 +55,000	+55%	+$1.1M	﹤0.01%	1712
2015 Q3	$2.02M	Buy	+100,800	New	+$2.99M	﹤0.01%	2114

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's TVTX Position: Q2 2026 in Review

Barclays reduced its Travere Therapeutics (TVTX) stake by 92% in Q2 2026, selling an estimated $10.2M and leaving 19,760 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2720.

Barclays first reported a position in TVTX in Q1 2014 and has held it in 44 quarters since. The position peaked at $14.7M in Q1 2025. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Barclays held 19,760 shares of Travere Therapeutics worth $1.12M as of Q2 2026.
Barclays sold 229,101 Travere Therapeutics shares in Q2 2026, an estimated $10.2M.
Travere Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2720 holding.
Barclays first reported a position in Travere Therapeutics in Q1 2014 and has held it in 44 quarters since.
Barclays's Travere Therapeutics position peaked at $14.7M in Q1 2025.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.